Key learning points: diabetes in older people with frailty
Professor Alan Sinclair explains how care should be personalised and targets adapted for older people with diabetes, including an assessment of frailty
Type 2 diabetes: the role of the practice pharmacist
Muhammad Siddiqur Rahman highlights the integral role of practice-based pharmacists in managing type 2 diabetes
Co-morbidities in type 2 diabetes
Dr Kevin Fernando describes eight common co-morbidities in patients with type 2 diabetes and how the co-existing conditions should be managed
Type 2 diabetes: what are the benefits and risks of glucose-lowering agents?
Dr Kevin Fernando explains how SIGN 154 offers evidence-based guidance on glucose control therapies for people with type 2 diabetes
Top tips: type 2 diabetes
Dr Kevin Fernando provides top tips on diagnosing and managing type 2 diabetes and identifying people at high risk
Test and reflect
Our multiple-choice questions (MCQs) are designed to help you test your knowledge and reflect on your learning after reading an article.
Educational resources
Guideline for the managed introduction of biosimilar basal insulin
Guidelines identified a need for clinical guidance in a specific area and approached Mylan for an educational grant to support the development of a working party guideline. This working party guideline was developed by Guidelines, and the Chair and members of the group were chosen by and convened by ...
Formulary decision guide: Ozempic®▼ (semaglutide)
Information intended for healthcare professionals only. This formulary decision guide was developed from content supplied by Novo Nordisk in a format developed by Guidelines in Practice. It has been reviewed by Novo Nordisk, who commissioned the development of the formulary decision guide.
Management of hyperglycaemia in type 2 diabetes, 2018: ADA/EASD consensus report
Watch this short animation, commissioned by Napp Pharmaceuticals Limited, to find out about the third joint consensus report on the management of hyperglycaemia in type 2 diabetes by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Semglee® ▼ (insulin glargine biosimilar)
This formulary decision guide was developed from content provided by Mylan Ltd in a format developed by Guidelines in Practice.
Related Guidelines summaries
-
Guideline for the managed introduction of biosimilar basal insulin
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.
-
NICE type 2 diabetes guideline
This summary provides recommendations on blood glucose targets, patient education, and includes a useful algorithm on blood glucose management
-
Type 2 diabetes treatment pathway comparison
This comparison table summarises recommendations on the management of hyperglycaemia in adults with type 2 diabetes from ADA/EASD, NICE, and SIGN.
-
Type 2 diabetes: frailty in older people
Summary covers glycaemic targets for older people, priorities for improving high-quality diabetes care, and a useful frailty assessment pathway.
-
NICE pancreatitis guideline
Summary of NICE guidance on pancreatitis covers managing complications, nutrition support, and referral for specialist treatment.